A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.